NCT04307797 - Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions

Type 2 DiabetesObesity

Interventions

DRUG

0.9% Sodium-chloride

Part A - 0.9% saline infusion during cardiac PET-MRI scan

DRUG

Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min

Part A - exenatide and glucagon infusion during cardiac PET-MRI scan

DRUG

Glucagon 12.5ng/kg/min and 0.9% saline

Part A - Glucagon and 0.9% saline infusion during PET-MRI scan

DRUG

0.9% Sodium-chloride

Part B - 0.9% saline infusion during 7T 31P MRS scan

DRUG

Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min

Part B - exenatide and glucagon infusion during 7T 31P MRS scan

DRUG

Glucagon 12.5ng/kg/min

Part B - Glucagon infusion during 7T 31P MRS scan

Trial Locations (1)

Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge, Cambridge